117 related articles for article (PubMed ID: 34464674)
21. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
22. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
23. Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip.
Wang Z; Yu BW; Rahman KM; Ahmad F; Sarkar FH
Mol Cancer Ther; 2008 Feb; 7(2):341-9. PubMed ID: 18281517
[TBL] [Abstract][Full Text] [Related]
24. Marine lipopeptide Iturin A inhibits Akt mediated GSK3β and FoxO3a signaling and triggers apoptosis in breast cancer.
Dey G; Bharti R; Dhanarajan G; Das S; Dey KK; Kumar BN; Sen R; Mandal M
Sci Rep; 2015 May; 5():10316. PubMed ID: 25974307
[TBL] [Abstract][Full Text] [Related]
25. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
26. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
27. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.
Yates JW; Dudley P; Cheng J; D'Cruz C; Davies BR
Cancer Chemother Pharmacol; 2015 Aug; 76(2):343-56. PubMed ID: 26092323
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells.
Rahman KW; Sarkar FH
Cancer Res; 2005 Jan; 65(1):364-71. PubMed ID: 15665315
[TBL] [Abstract][Full Text] [Related]
29. Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis.
Choi AR; Jung MJ; Kim JH; Yoon S
Anticancer Res; 2015 Sep; 35(9):4741-7. PubMed ID: 26254364
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer.
Bhattacharjee M; Upadhyay P; Sarker S; Basu A; Das S; Ghosh A; Ghosh S; Adhikary A
Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129695. PubMed ID: 32735937
[TBL] [Abstract][Full Text] [Related]
32. Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.
Searle EJ; Telfer BA; Mukherjee D; Forster DM; Davies BR; Williams KJ; Stratford IJ; Illidge TM
EMBO Mol Med; 2017 Dec; 9(12):1646-1659. PubMed ID: 29084756
[TBL] [Abstract][Full Text] [Related]
33. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
34. Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER
Robertson JFR; Coleman RE; Cheung KL; Evans A; Holcombe C; Skene A; Rea D; Ahmed S; Jahan A; Horgan K; Rauchhaus P; Littleford R; Cheung SYA; Cullberg M; de Bruin EC; Koulai L; Lindemann JPO; Pass M; Rugman P; Schiavon G; Deb R; Finlay P; Foxley A; Gee JMW
Clin Cancer Res; 2020 Apr; 26(7):1574-1585. PubMed ID: 31836609
[TBL] [Abstract][Full Text] [Related]
35. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
36. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
37. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
[TBL] [Abstract][Full Text] [Related]
38. Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT.
Choi AR; Kim JH; Woo YH; Cheon JH; Kim HS; Yoon S
Anticancer Res; 2016 Nov; 36(11):5849-5858. PubMed ID: 27793908
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.
Yi YW; Hong W; Kang HJ; Kim HJ; Zhao W; Wang A; Seong YS; Bae I
J Cell Mol Med; 2013 May; 17(5):648-56. PubMed ID: 23601074
[TBL] [Abstract][Full Text] [Related]
40. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Yan J; Yang S; Tian H; Zhang Y; Zhao H
Cell Death Dis; 2020 Nov; 11(11):943. PubMed ID: 33139695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
